M. Cruz Fernández-Espartero

Hospital La Luz

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jordi Gratacós

Universitat Autònoma de Barcelona

Loreto Carmona

Instituto de Salud Musculoesquelética

Teresa Clavaguera

Hospital Santa Caterina

R. Ortega Castro

Instituto Maimónides de Investigación Biomédica de Córdoba

E. Muñoz Gomariz

University of Córdoba

Pilar Font

University of Córdoba

Antonio Juan Más

Hospital Son Llatzer

Pedro Zarco

Hospital Universitario Fundación Alcorcón

Pilar Fernández Dapica

Hospital Universitario 12 De Octubre

Manuel Pujol Busquets

Mútua Terrassa

Cooperative Institutions

Center for Rheumatology

Instituto de Investigación Marqués de Valdecilla

Marqués de Valdecilla University Hospital

Hospital Universitario Reina Sofía

Bellvitge University Hospital

Hospital Universitario Fundación Alcorcón

Universidad de Cantabria

Instituto Maimónides de Investigación Biomédica de Córdoba

University of Córdoba

Universitat de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

Seminars in Arthritis and Rheumatism (2011)

M. Cruz Fernández-Espartero Beatriz Pérez-Zafrilla Antonio Naranjo Carmen Esteban Ana M. Ortiz

Optic neuritis

Discontinuation

10.1016/j.semarthrit.2011.05.003

Cite

Citations (72)

Lesiones cutáneas ampollosas en un paciente con lupus eritematoso sistémico

Revista Clínica Española (2001)

Manuel Rodríguez M. Cruz Fernández-Espartero J. de la Mata J.A. Satué

10.1016/s0014-2565(01)70826-0

Cite

Citations (0)

AB0588 Golimumab in Refractory Uveitis to Other Anti-TNFα Drugs

Annals of the Rheumatic Diseases (2014)

F. Ortíz-Sanjuán Ricardo Blanco J. Cañal Miguel Cordero‐Coma Alfredo Adán

Objectives

To assess the efficacy and safety of Golimumab in patients with refractory uveitis to other anti-TNFα drugs.

Methods

Study of patients from a single center with refractory uveitis to previous standard synthetic immunosuppressive drugs and at least 1 anti-TNFα drug. Golimumab was given at the standard dose of 50 mg/sc/month.

Results

A total of 25 patients (39 affected eyes) (19 men/6 women); mean age, 32.5±8.9 years (range 11-47); fulfilled the above-mentioned criteria. In 14 cases uveitis was bilateral and in 11 cases it was unilateral. The underlying diseases were spondylarthritis (n=7), psoriatic arthropathy (n=4), juvenile idiopathic arthritis (n=4), sarcoidosis (n=3), Behçet disease (n=2), uveitis associated with HLA-B27 and ulcerative colitis (n=1), pars planitis (n=1) and Vogt-Koyanagi-Harada (n=1). Besides oral steroids and before Golimumab onset they had received: intraocular corticosteroids (n=10), methylprednisolone i.v. boluses (n=6), methotrexate (n=20), cyclosporine A (n=6), azathioprine (n=6), adalimumab (n=17), infliximab (n=14), abatacept (n=2) and certolizumab (n=1). Golimumab was started because inefficacy (n=23) and/or toxicity (n=2) to other biologics. Golimumab was used as monotherapy (n=9) or in combination with methotrexate (n=9), azathioprine (n=3), leflunomide (n=2) and mycophenolate (n=2). There was a rapid (from 1st week) and maintained (1st year) improvement of visual acuity, anterior chamber inflammation, vitritis and OCT. The mean OCT improved from 319.9±77.9 μm (baseline) to 270.2±54.8 μm (1st month) (p<0.01) and to 244.3±43.2 μm (1st year) (p=0.02). After a mean follow-up of 13.3±8.3 (range 2-30) months the most important side-effects observed were local erythema in injection area (n=1) and herpes zoster (n=1).

Conclusions

Golimumab seems an effective and safe treatment for those patients with uveitis even refractory to other anti-TNFα drugs.

Acknowledgements

This study was supported by a grant from “Fondo de Investigaciones Sanitarias” PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from “Instituto de Salud Carlos III” (ISCIII) (Spain).

Disclosure of Interest

None declared

DOI

10.1136/annrheumdis-2014-eular.4758

Golimumab

10.1136/annrheumdis-2014-eular.4758

Cite

Citations (0)

Adolescente con dolor lumbar

Reumatología Clínica (2006)

M. Cruz Fernández-Espartero Jacqueline Usón-Jaeger Roberto Miguélez-Sánchez Mercedes Morcillo-Valle

10.1016/s1699-258x(06)73037-6

Cite

Citations (2)

Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER

Reumatología Clínica (2013)

R. Ortega Castro Pilar Font Carmen Castro Jerusalem Calvo‐Gutiérrez E. Muñoz Gomariz

10.1016/j.reuma.2012.09.008

Cite

Citations (24)

THU0220 Regisponserbio, Baseline Visit: Differences Between Prevalent and Incidents Cases

Annals of the Rheumatic Diseases (2015)

Maria Moreno Xavier Juanola Victoria Navarro‐Compán Milagros del Rosario Vergara Aburto de Aparicio A. Sellas

Background

Disease registries are a very useful tool to clarify and analyze in clinical practice differences between patients regarding epidemiology, prognostic, therapeutic efficacy, quality of life and socio-economic characteristics.

Objectives

To evaluate the main differences at the beginning of the current biological therapy between the prevalent and incident patients included in REGISPONSERBIO.

Methods

REGISPONSERBIO is a Spanish multicenter (17), prospective registry (3 year-follow-up, with clinical controls every six months) of patients with axial SpA (ASAS criteria) under biological treatment. All patients included should be under biologic treatment and have a minimum data set necessary to achieve the main objectives planed for the registry. The inclusion period extended between September 2013 and December 2014. The registry included two groups of patients: a) prevalent cases (patients receiving biological treatment prior to baseline visit) b) incident cases (patients who started biological therapy at the inclusion in the registry). In all patients the following data was collected at baseline: age, disease and treatment duration, gender, HLA B27, Body Mass Index (BMI), BASDAI, BASFI, CRP, ESR, metrological data, ASQoL, WAPAI, extra-articular manifestations, comorbidities, radiological study, biological treatment at the time of inclusion in the registry and concomitant treatments. For this study, characteristics between prevalent and incident cases were compared using t-Student and chi-square tests. Results are shown as mean (standard deviation) or relative frequencies.

Results

This registry included 258 patients, 174 out of 258 (67%) were prevalent cases. The group of prevalent patients showed higher disease evolution: 15 (11) vs 8 (11) years (p<0.001), higher proportion of males: 144 (83%) vs 57 (69%) (p=0.01), less proportion of non radiographic axial spondylarthritis: 6 (3%) vs 12 (14%) (p=0.001) and higher proportion of HLA-B27 positive 145 (84%) vs 57 (69%) although this latter result did not reach statistical significance (p=0.06).

Conclusions

The observed data suggest that the profile of patients starting biological therapy seems to be changing in the last years.

Disclosure of Interest

None declared

Concomitant

BASFI

10.1136/annrheumdis-2015-eular.5110

Cite

Citations (0)

Different Clinical Expression of Patients With Ankylosing Spondylitis According to Gender in Relation to Time Since Onset of Disease. Data From REGISPONSER

Reumatología Clínica (English Edition) (2013)

R. Ortega Castro Pilar Font Carmen Castro Jerusalem Calvo‐Gutiérrez E. Muñoz Gomariz

BASFI

Spondylitis

Erythrocyte sedimentation rate

10.1016/j.reumae.2012.09.004

Cite

Citations (24)

Lupus eritematoso sistémico (II) y síndrome antifosfolípido

Medicine - Programa de Formación Médica Continuada Acreditado (2009)

M. Cruz Fernández-Espartero

10.1016/s0304-5412(09)71057-1

Cite

Citations (0)

Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

Seminars in Arthritis and Rheumatism (2010)

M. Cruz Fernández-Espartero Beatriz Pérez-Zafrilla Antonio Naranjo Carmen Bartolomé Esteban Ana M. Ortiz

Optic neuritis

Discontinuation

10.1016/j.semarthrit.2010.06.004

Cite

Citations (1)

Methotrexate-induced nephrogenic diabetes insipidus: first case report

British journal of rheumatology (2002)

M. Cruz Fernández-Espartero

Methotrexate-induced nephrogenic diabetes insipidus: first case report SIR, Methotrexate (MTX) has become the dominant second-line agent in the treatment of patients with

Nephrogenic diabetes insipidus

10.1093/rheumatology/41.2.233

Cite

Citations (7)